Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
Current Oncology · 07.11.2013 · 21 (1) · 41
DOI: 10.3747/co.21.1327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 07.11.2013. Verfasst von C L Attard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cornerstone Research Group Inc., Burlington, ON. Die Arbeit wurde bisher 42-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cornerstone Research Group Inc., Burlington, ON.
- Sanofi Canada, Laval, QC.
- Princess Margaret Hospital, Toronto, ON.
Zitieren
APA
Attard, C. L., Brown, S., Alloul, K., & Moore, M. J. (2013). Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Current Oncology, 21(1), 41. https://doi.org/10.3747/co.21.1327
Vancouver
Attard CL, Brown S, Alloul K, Moore MJ. Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Current Oncology. 2013;21(1):41. doi:10.3747/co.21.1327
BibTeX
@article{Attard2013,
author = {Attard, C L and Brown, S and Alloul, K and Moore, M J},
title = {Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer},
journal = {Current Oncology},
year = {2013},
volume = {21},
number = {1},
pages = {41},
doi = {10.3747/co.21.1327}
}
EUVIMED